Cardiovascular and renal outcomes with empagliflozin in heart failure

By Packer M, Anker SD, Butler J, et al
Published August 29, 2020

Key Takeaways

This double-blind trial was undertaken to evaluate a composite of cardiovascular mortality or hospitalization for worsening heart failure among patients (n = 3,730) with class II, III, or IV heart failure and an ejection fraction of 40% or less who were randomized to receive empagliflozin (10 mg once daily) or placebo, in addition to recommended therapy. The goal was to investigate the impacts of sodium–glucose cotransporter 2 inhibitors in patients across the broad spectrum of heart failure, including those with a markedly decreased ejection fraction. Findings revealed a lower risk of cardiovascular death or hospitalization for heart failure in correlation with treatment with empagliflozin vs placebo, irrespective of the presence or absence of diabetes, among patients receiving recommended therapy for heart failure.

Read the full article on New England Journal of Medicine.

Share with emailShare to FacebookShare to LinkedInShare to Twitter